Achillion Pharmaceuticals, Inc.

Bristol-Myers Squibb Compnay

Viiv Healthcare UK (No.5) Limited

Viiv Healthcare UK Limited

Kyle J Eastman

Jason Allan Wiles

Venkat Rao Gadhachanda

John F Kadow

Avinash S Phadke

Dawei Chen

Atul Agarwal

Kyle E Parcella

Joel Charles Barrish

Godwin Pais

William J Greenlee

Milind Deshpande

Xiangzhu Wang

Akihiro Hashimoto

Qiuping Wang

Tao Wang

Zhongxing Zhang

B Narasimhulu Naidu

Zhiwei Yin

Kevin M Peese

Kap-Sun Yeung

John A Bender

Manoj Patel

Prasanna Sivaprakasam

Timothy P Connolly

Yong Tu

Zhong Yang

Narasimhulu B Naidu

This disclosure provides pharmaceutical compounds to treat medical disorders, such as complement-mediated disorders, including complement Cl-mediated disorders.

Pharmaceutical compounds for the treatment of complement mediated disorders

Macrocyclic Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, Formula V, Formula VI, Formula VII, and Formula VIII or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Macrocyclic compounds for treatment of medical disorders

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, Formula IV, and Formula V, or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders

Complement Factor D inhibitors, pharmaceutical compositions, and uses thereof, as well as processes for their manufacture are provided. The compounds provided include Formula I, Formula II, Formula III, and Formula IV or a pharmaceutically acceptable salt, prodrug, isotopic analog, N-oxide, or isolated isomer thereof, optionally in a pharmaceutically acceptable composition. The inhibitors described herein target Factor D and inhibit or regulate the complement cascade.

Pharmaceutical compounds for treatment of medical disorders

Compounds, methods of use, and processes for making inhibitors of complement factor D or a pharmaceutically acceptable salt or composition thereof are provided. The inhibitors described herein target factor D and inhibit or regulate the complement cascade. The inhibitors of factor D described herein reduce excessive activation of complement.

Macrocyclic compounds for the treatment of medical disorders

Disclosed are compounds of Formula I, including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV. 

Pyridin-3-yl acetic acid derivatives as inhibitors of human immunodeficiency virus replication

Compounds of Formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV: 

Substituted 2-phenyl (AZA)benzofuran compounds for the treatment of hepatitis C

Disclosed are compounds of Formula (I), including pharmaceutically acceptable salts, pharmaceutical compositions comprising the compounds, methods for making the compounds and their use in inhibiting HIV integrase and treating those infected with HIV or AIDS. In the compounds of formula (I), Ris selected from hydrogen, alkyl, or cycloalkyl; Ris selected from tetrahydroisoquinolinyl and is substituted with 1 Rsubstituent and also with 0-3 halo or alkyl substituents; Ris selected from azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, homopiperidinyl, homopiperazinyl, or homomorpholinyl, and is substituted with 0-3 substituents selected from cyano, halo, alkyl, haloalkyl, alkoxy, and haloalkoxy; Ris selected from alkyl or haloalkyl; Ris alkyl; Ris selected from Ar, (Ar)alkyl, (chromanyl)alkyl, cyanocycloalkyl or (dihydrobenzodioxinyl)alkyl; and Aris phenyl substituted with 0-5 substituents selected from cyano, halo, alkyl, cycloalkyl, haloalkyl, hydroxy, alkoxy, haloalkoxy, (hydroxy)alkoxy, (alkoxy)alkoxy, phenoxy, benzyloxy, carboxy, phenyl, and cyanocycloalkyl. 

Substituted pyridines as inhibitors of human immunodeficiency virus replication

The disclosure generally relates to compounds of formula I, including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection. 

Imidazo[1,2-A]pyridine derivatives for use as inhibitors of human immunodeficiency virus replication

Compounds of formula I, including their salts, as well as compositions and methods of using the compounds are set forth. The compounds have activity against hepatitis C virus (HCV) and may be useful in treating those infected with HCV. 

Furopyridine compounds for the treatment of hepatitis C

Growing community of inventors

Wallingford, CT, United States of America

Kyle J Eastman